Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia ™) in peanut allergy: a profile of its use

AbstractPeanut (Arachis hypogaea) allergen powder-dnfp (Palforzia ™; hereafter referred to as PTAH), is the first oral immunotherapy approved in the USA and European Commission for mitigating allergic reactions in children aged 4–17 years with peanut allergy. In the pivotal phase 3 studies in patients with peanut allergy, relative to placebo, PTAH significantl y desensitized to peanut protein and reduced severity of allergic reactions to accidental peanut exposure, together with improvements in food allergy-related quality of life. The clinical benefits of PTAH were maintained with continued treatment for up to 2 years. Most adverse events with PTAH, incl uding systemic allergic reactions, were of mild to moderate severity. Frequency and severity of adverse events decreased with continued treatment.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research